STROBE
Financiado
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular dege...
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration
This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to impr...
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration
This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2015-04-10
Fecha Fin: 2015-10-31
Fecha Fin: 2015-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2015-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
CRITICAL PHARMACEUTICALS LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
309.57K€ |
Participante